Cord Blood Stem Cells Bring The Promise Of New Regenerative Medicine
Cord blood stem cells today are successfully used in saving lives. Used in transplant medicine for over 20-years, newborn, placental fluid is the initiative behind regenerative medical research, for treating brain injuries, juvenile diabetes, cerebral palsy and cardiac repair. These building blocks of organ tissue, blood and immunity are the future of medicine now.
At childbirth, the placenta and umbilical cord blood hold a wealth of newborn stem cells that are changing the face of medicine with new directions of advanced treatments for many conditions. The controversy surrounding stem cell research is not applicable to derivatives of placental material, but is related to lab generated embryonic material.
Comparatively, this cellular material has many advantages over the use of bone marrow for patients battling hematologic cancers and/or disorders or undergoing chemotherapy. Easy acquisition, timely availability and application, reduced incidence of transplant complications and no-expiration date in preservation through freezing, qualifies this as the premier option in regenerative medicine. This process provides critical patients requiring hematologic and immunologic cells the quickest, safest route for treatment.
Science has led to the discovery of multi-potent stem cells, predominantly occurring within the placental tissues. The richer the concentration of cellular activity, the more beneficial the treatment outcome, with fewer side effects and shorter recovery time. Harvesting is performed directly following childbirth when the fluid is syringed from the placental tissues via the umbilical cord.
As research uncovers the suitability of effective, regenerative procedures, the number of people impacted by the growing list of treatable diseases will correspondingly increase. This emergent field of medicine uses placental cells to encourage the body to repair tissues impacted by autoimmune disease, cardiovascular conditions and neuro-muscular diseases. As the feasibility of this treatment increases, so will the need for banked transplant material.
As the viable applications for regenerative medicine grow, families may want to consider the option of banking autologous placental tissue for the possibility of its relevance in the future. Those who have prepared through the storage of this transplant medicine will be eliminating the risk of complicating factors, such as rejection.
The most serious complication related to transplantation is seen in (GVHD) Graft vs Host Disease. This life-threatening occurrence is most commonly seen with the use of non-family, placental fluid donors. The body perceives the transplant material as a foreign invader and reacts by attacking itself, resulting in rejection that can lead to death. This terminal complication is avoided through family-banked, amniotic, cord blood transplants.
Innovative ideas have initiated clinical trials to study the long-term results in placental fluid infusions in juveniles with a recent confirmation of Type 1 diabetes in comparison to those treated with typical insulin injections. The diversity of regenerative applications is being studied in trials for stroke, birth injuries, lupus, and reparable capabilities in damage incurred with cardiac events.
Following the collection procedure, cord blood stem cells are protected and preserved through cryopreservation. This method of freezing abates aging, environmental damage and viruses that can create potential future medical issues. Storage is either via private banks that maintain genetic exclusivity and are the financial responsibility of the donor family or public banks available for use by the general public.
At childbirth, the placenta and umbilical cord blood hold a wealth of newborn stem cells that are changing the face of medicine with new directions of advanced treatments for many conditions. The controversy surrounding stem cell research is not applicable to derivatives of placental material, but is related to lab generated embryonic material.
Comparatively, this cellular material has many advantages over the use of bone marrow for patients battling hematologic cancers and/or disorders or undergoing chemotherapy. Easy acquisition, timely availability and application, reduced incidence of transplant complications and no-expiration date in preservation through freezing, qualifies this as the premier option in regenerative medicine. This process provides critical patients requiring hematologic and immunologic cells the quickest, safest route for treatment.
Science has led to the discovery of multi-potent stem cells, predominantly occurring within the placental tissues. The richer the concentration of cellular activity, the more beneficial the treatment outcome, with fewer side effects and shorter recovery time. Harvesting is performed directly following childbirth when the fluid is syringed from the placental tissues via the umbilical cord.
As research uncovers the suitability of effective, regenerative procedures, the number of people impacted by the growing list of treatable diseases will correspondingly increase. This emergent field of medicine uses placental cells to encourage the body to repair tissues impacted by autoimmune disease, cardiovascular conditions and neuro-muscular diseases. As the feasibility of this treatment increases, so will the need for banked transplant material.
As the viable applications for regenerative medicine grow, families may want to consider the option of banking autologous placental tissue for the possibility of its relevance in the future. Those who have prepared through the storage of this transplant medicine will be eliminating the risk of complicating factors, such as rejection.
The most serious complication related to transplantation is seen in (GVHD) Graft vs Host Disease. This life-threatening occurrence is most commonly seen with the use of non-family, placental fluid donors. The body perceives the transplant material as a foreign invader and reacts by attacking itself, resulting in rejection that can lead to death. This terminal complication is avoided through family-banked, amniotic, cord blood transplants.
Innovative ideas have initiated clinical trials to study the long-term results in placental fluid infusions in juveniles with a recent confirmation of Type 1 diabetes in comparison to those treated with typical insulin injections. The diversity of regenerative applications is being studied in trials for stroke, birth injuries, lupus, and reparable capabilities in damage incurred with cardiac events.
Following the collection procedure, cord blood stem cells are protected and preserved through cryopreservation. This method of freezing abates aging, environmental damage and viruses that can create potential future medical issues. Storage is either via private banks that maintain genetic exclusivity and are the financial responsibility of the donor family or public banks available for use by the general public.
About the Author:
When looking for a reliable bankruptcy Pickering counselling firm, be sure to hire from Durham's most experienced company. With years of experience in debt consolidation and credit counselling Pickering, we can help you with your financial needs.